Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen and Theravance Biopharma to develop new bowel disease therapy

Janssen and Theravance Biopharma to develop new bowel disease therapy

8th February 2018

Janssen has announced a new drug research partnership with Theravance Biopharma that will focus on the development of a promising new bowel disease therapy.

The companies will be partnering to further the development of TD-1473, a first-in-class oral, gastrointestinal restricted pan-Janus kinase inhibitor for the treatment of inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis.

Under the terms of the agreement, Theravance Biopharma will complete a phase II study of the drug in Crohn's disease and a phase IIb/III induction and maintenance study in ulcerative colitis, both of which are planned to start in 2018.

After this point, Janssen may elect to enter into an exclusive licence arrangement for the programme, after which it would take the lead on the subsequent development of the drug, with Theravance Biopharma retaining an option to co-commercialise the therapy in the US.

Dr Scott Plevy, vice-president and disease area leader for inflammatory bowel disease at Janssen Research and Development, said: "We look forward to advancing this promising, oral, drug candidate through clinical development as we continue to address the significant unmet needs of people living with Crohn's disease and ulcerative colitis around the world."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.